There was a significantly higher proportion of diagnosed PAD in the deep DFU groups (D−/I− 38.2%; D−/I+ 36.4%; D+/I− 51.4%; D+/I+ 63.0%; p<0.001) and a significantly lower proportion of SGLT2 inhibitor use (D−/I− 29.9%; D−/I+ 29.1%; D+/I− 17.1%; D+/I+ 18.1%; p=0.047). This evidence concerns the gene SLC5A2 and peripheral arterial disease.